Ruqayyah Snyder
The COVID-19 pandemic has brought about many changes and challenges, with Australia being no exception. While the Australian government provides free or subsidised healthcare for its citizens through Medicare, it is important to understand what this entails in the context of COVID-19 treatment. This includes understanding the eligibility criteria for oral antiviral treatments, the role of vaccinations, and any mental health support available.
| Characteristics | Values |
|---|---|
| COVID-19 oral treatment | Subsidised under the Pharmaceutical Benefits Scheme for eligible people |
| COVID-19 | A notifiable disease in every state and territory |
| Oral antiviral treatments | Should be started as soon as possible after symptoms begin |
| Eligibility for oral antiviral treatments | People aged 70 and older, people aged 50 and older with 2 additional risk factors, Aboriginal or Torres Strait Islander people aged 30 and older with 1 additional risk factor |
| Ivermectin | Not endorsed as a COVID-19 treatment by the Therapeutic Goods Administration, the National Covid Evidence Taskforce, or the World Health Organization |
Explore related products
What You'll Learn
- COVID-19 oral treatments are subsidised under the Pharmaceutical Benefits Scheme
- COVID-19 is a notifiable disease in every Australian state and territory
- The National Covid Evidence Taskforce advises against the use of ivermectin for COVID-19 treatment
- The Australian Government provides free mental health support for those impacted by COVID-19
- COVID-19 vaccination is recommended for all people aged 18 years and older
COVID-19 oral treatments are subsidised under the Pharmaceutical Benefits Scheme
The Australian Government has expanded access to COVID-19 oral treatments under the Pharmaceutical Benefits Scheme (PBS). This means that eligible individuals can access subsidised oral antiviral treatments, such as Paxlovid, which has been shown to significantly reduce the risk of hospitalisation and death from COVID-19.
From 1 April 2023, the Albanese Government expanded eligibility for the PBS-subsidised Paxlovid to include Australians aged 60 to 69 with at least one risk factor for severe illness. Previously, only those with two risk factors were eligible. This change was recommended by the independent Pharmaceutical Benefits Advisory Committee (PBAC) and is expected to help reduce pressure on Australian hospitals.
The cost for each course of treatment under the PBS is the standard co-payment amount: $30 for general patients and $7.30 for concession cardholders. It is important to note that not all patients can take Paxlovid. For example, people with severe kidney or liver impairment or those taking certain medications for heart, mental health, or cancer conditions may not be suitable for Paxlovid.
In addition to oral treatments, the Australian Government has also provided access to free or subsidised mental health services through Medicare. Eligible individuals can access up to 10 free psychology or therapy sessions per year with a mental health treatment plan from their GP. These services aim to provide support for those experiencing mental health challenges due to the impacts of the COVID-19 pandemic.
Overall, the Australian Government's efforts to subsidise COVID-19 oral treatments under the PBS and provide access to mental health services through Medicare demonstrate a commitment to ensuring that Australians can access the necessary healthcare during the pandemic.
Fidget Spinners: Banned or a Spin in Australia?
You may want to see also
Explore related products
COVID-19 is a notifiable disease in every Australian state and territory
The Australian Government subsidises COVID-19 oral treatment under the Pharmaceutical Benefits Scheme for eligible people. This means that eligible Australians can access COVID-19 treatment without worrying about the financial strain. In addition to this, the Federal Government has also expanded the number of Medicare sessions from 10 to 20, giving eligible Australians an extra 10 sessions. As of 2023, this initiative has been rolled back, but Australians can still claim up to 10 free sessions with a mental health professional. To be eligible for free therapy, you need to enrol in Medicare, which will assist with the cost of healthcare in Australia.
Eating Right After Tonsillectomy: Adult Australian's Guide
You may want to see also
Explore related products
The National Covid Evidence Taskforce advises against the use of ivermectin for COVID-19 treatment
In Australia, COVID-19 oral treatment is subsidised under the Pharmaceutical Benefits Scheme for eligible people. The Communicable Diseases Network Australia (CDNA) provides public health units with nationally consistent guidance for responding to COVID-19 infection.
While there is financial support for COVID-19 treatment in Australia, the National Clinical Evidence Taskforce (NCET) advises against the use of ivermectin for the prevention or treatment of COVID-19. Ivermectin is a prescription-only medicine in the Poisons Standard, and its use was restricted in September 2021 due to concerns about consumers' safety. The TGA does not endorse off-label prescribing of ivermectin for COVID-19, as clinical studies have demonstrated that it does not improve outcomes in patients with COVID-19. The World Health Organization and other similar bodies worldwide share this stance.
Ivermectin is approved for the treatment of river blindness, threadworm of the intestines, and scabies. It is also authorised for veterinary use for internal and external parasites in a wide range of animal species. However, its use for COVID-19 is not supported by the available data, and it is not authorised for this purpose in the EU.
While some studies have shown potential benefits, most studies have been small and had limitations such as different dosing regimens and the use of concomitant medications. As a result, it has been concluded that the evidence is insufficient to support the use of ivermectin for COVID-19 outside well-designed clinical trials. There are concerns about potential toxicity when using higher than approved doses of ivermectin, which may be necessary to obtain effective concentrations in the lungs.
From 1 June 2023, the prescribing of oral ivermectin for 'off-label' uses will no longer be restricted to specialists, but it is important to note that this does not change the advice against using ivermectin for COVID-19 treatment or prevention.
Applying for a Medicare Card: Australia's Guide for Beginners
You may want to see also
Explore related products
The Australian Government provides free mental health support for those impacted by COVID-19
The COVID-19 pandemic has had a significant impact on the mental health of many Australians. The Australian Government has responded by providing free mental health support for those affected by the pandemic.
The Government has allocated funding to enhance mental health services and address the increased demand for support. For example, the ACT Government announced a $4.5 million COVID-19 mental health support package, which included funding for Canberra Health Services to expand their programs supporting people experiencing a mental health crisis. This package also included funding for Canberra's LGBTIQ+ community to ensure that key services could continue to be delivered.
At a national level, the Australian Government has taken steps to ensure that COVID-19 treatment is accessible and affordable. COVID-19 oral treatments are subsidised under the Pharmaceutical Benefits Scheme for eligible individuals. Additionally, the Government has provided free or subsidised access to COVID-19 vaccinations, which are recommended for all people aged 18 and older, as well as children aged 6 months to under 18 with certain medical conditions.
To support the mental health of Australians impacted by COVID-19, the Government has also expanded access to mental health services through Medicare. Eligible individuals can access up to 10 free psychology sessions per year with a mental health treatment plan from their GP. Bulk billing with a therapist who offers this service can make these sessions completely free, ensuring that cost is not a barrier to seeking support.
Various organisations also provide mental health support for specific groups, such as employees, children and young people, and the LGBTIQA+ community. For instance, the NSW Government has provided information on managing employee wellbeing during COVID-19, and Kids Helpline offers free and confidential counselling for young people aged 5 to 25. QLife provides anonymous and free peer support for LGBTIQA+ individuals, and the Australian Network on Disability has developed resources to support employees with disabilities during the pandemic. These initiatives ensure that Australians impacted by COVID-19 have access to the mental health support they need.
Applying for Australian PR: A Guide for Bangladeshis
You may want to see also
Explore related products
COVID-19 vaccination is recommended for all people aged 18 years and older
In Australia, COVID-19 oral treatment is subsidised under the Pharmaceutical Benefits Scheme for eligible people. The Communicable Diseases Network Australia (CDNA) provides public health units with nationally consistent guidance for responding to COVID-19 infection.
Regarding COVID-19 vaccination, it is recommended for all people aged 18 years and older. This recommendation is supported by various organisations and governments worldwide. For instance, in New South Wales, the government advises that COVID-19 vaccination is recommended for all people aged 18 and older. Additionally, it is also recommended for children aged 6 months to under 18 years with medical conditions that increase the risk of severe disease or death from COVID-19.
The Australian Government provides detailed information about COVID-19 vaccination, including the different types of vaccines available and their safety. It is recommended to speak to a doctor or vaccination provider to understand the risks and benefits of vaccination based on individual circumstances.
Furthermore, it is important to note that COVID-19 can be caught more than once, so even those who have recently recovered from COVID-19 should still receive their recommended vaccination. Vaccination is likely to provide better protection compared to infection alone.
In addition to vaccination, the Australian Government has also provided support for mental health services. Due to the impacts of COVID-19, the Federal Government previously expanded the number of Medicare-rebated psychology sessions from 10 to 20. As of 2023, this initiative was rolled back, but eligible Australians can still access up to 10 free therapy sessions with a mental health treatment plan. Bulk billing can also make therapy completely free, where Medicare covers the entire cost.
Dallas to Australia: Best Flight Routes and Airports
You may want to see also
Frequently asked questions
COVID-19 oral antiviral treatments are free for people who are at a higher risk of severe illness. This includes people who are 70 years of age or older, 50 years of age or older with two additional risk factors, Aboriginal or Torres Strait Islander and 30 years of age or older with one additional risk factor, and people living with disabilities.
To be eligible for free COVID-19 treatment in Australia, individuals must meet the criteria for being at higher risk of severe illness. Additionally, it is important to note that pregnant or breastfeeding individuals should not take oral COVID-19 treatments and should instead ensure they are up to date with their COVID-19 vaccinations.
One example of a free COVID-19 treatment in Australia is Paxlovid®, an oral treatment for individuals prescribed birth control pills. However, it is recommended to use extra contraception during and after treatment as it may affect the effectiveness of the birth control pill.
